Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Platinum-based drugs are first-line chemotherapies for various cancers, but tumor resistance limits their efficacy.
• Chemoresistance is often driven by enhanced DNA repair and telomere maintenance mediated by the Mre11/Rad50/Nbs1 (MRN) complex.
• Targeting the MRN complex presents a potential strategy to sensitize tumors to DNA-damaging agents.

Purpose of the Study:

• To investigate whether impairing MRN complex function can sensitize tumor cells to cisplatin.
• To develop and test a novel therapeutic approach using a dominant-negative mutant RAD50 gene to disrupt MRN function.

Main Methods:

• Designed a dominant-negative adenoviral vector expressing a mutant RAD50 gene.
• Downregulated MRN expression and disrupted MRN function in human squamous cell carcinoma cells.
• Evaluated the combination of cisplatin and mutant RAD50 therapy in vitro and in vivo using cisplatin-resistant xenografts.

Main Results:

• The mutant RAD50 therapy significantly downregulated MRN expression and disrupted MRN function.
• Combination therapy demonstrated significant tumor cytotoxicity in vitro, increasing DNA damage and telomere shortening.
• In vivo studies showed dramatic tumor regression and increased apoptosis in cisplatin-resistant xenografts.

Conclusions:

• Targeted disruption of RAD50 function is a novel and effective chemosensitizing strategy for overcoming cisplatin resistance.
• This approach holds promise for treating various chemoresistant cancers and improving patient outcomes.
• Further research into this strategy could lead to new therapeutic options for difficult-to-treat malignancies.